Background
==========

Riociguat, a soluble guanylate cyclase stimulator, is currently under investigation for the treatment of pulmonary hypertension. The present studies investigated the influence of omeprazole and AlOH/MgOH on riociguat absorption and bioavailability.

Methods
=======

The pharmacokinetics of oral, single-dose, immediate-release riociguat 2.5 mg were characterized in two open-label, randomized, crossover studies in healthy males. In the first study, subjects pretreated for 4 days with once-daily omeprazole 40 mg received co-treatment with omeprazole + riociguat or riociguat alone (no pretreatment) on Day 5 (n=12). In the second study, subjects received co-treatment with 10 mL AlOH/MgOH + riociguat or riociguat alone (n=12). Pharmacokinetic characteristics were analyzed assuming log-normally distributed data. Safety and tolerability were also assessed.

Results
=======

Riociguat bioavailability was decreased by pre- and co-treatment with omeprazole, with a mean decrease in C~max~ of 35% and a mean decrease in AUC of 26% (Table [1](#T1){ref-type="table"}; Figure [1](#F1){ref-type="fig"}). Co-treatment with 10 mL AlOH/MgOH resulted in a mean decrease in C~max~ of 56% and a mean decrease in AUC of 34% (Table [1](#T1){ref-type="table"}; Figure [2](#F2){ref-type="fig"}). In the riociguat/omeprazole study, adverse events (AEs) were reported in 4 (33%) subjects receiving riociguat alone and in 5 (42%) subjects receiving riociguat + omeprazole, with no AEs reported during the omeprazole pretreatment phase. The most commonly reported AEs were headache (9 events in 8 subjects; 5 drug-related events) and flushing (3 events in 2 subjects; all drug-related). In the riociguat/AlOH/MgOH study, AEs were reported in 9 (75%) subjects receiving riociguat alone and in 8 (67%) subjects receiving riociguat + AlOH/MgOH. The most commonly reported AEs were headache (12 events in 7 subjects; all drug-related), rhinitis (3 events in 3 subjects; no drug-related events), nasal congestion (3 events in 2 subjects; 2 drug-related events), and upper abdominal pain (3 events in 2 subjects; no drug-related events). No serious AEs were reported in either study and all AEs resolved by the end of the observation period.

###### 

Riociguat pharmacokinetic parameters (geometric means and coefficients of variation)

                  Riociguat/omeprazole study   Riociguat/AlOH/MgOH study                                         
  --------------- ---------------------------- --------------------------- ------- ------ ------- ------ ------- ------
  AUC (µg⋅h/L)    587.9                        71.9                        432.8   79.8   465.9   68.2   309.6   87.2
  C~max~ (µg/L)   73.8                         26.6                        48.1    33.8   80.8    38.4   35.5    57.1
  t~max~ (h)      3.0                          --                          3.0     --     1.0     --     2.5     --
  t~1/2~ (h)      7.9                          46.4                        9.0     25.4   5.9     44.4   8.6     53.8
  CL/f            4.3                          71.9                        5.8     79.8   5.4     68.2   8.1     87.2

AUC, area under plasma concentration--time curve; CL/f, total riociguat clearance from plasma; C~max~, maximum riociguat plasma concentration; CV, coefficient of variation; GM, geometric mean; t~1/2~, elimination half-life; t~max~, time to reach C~max~.

^a^Data are mean except t~max~, which is median.
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Conclusion
==========

Treatment with riociguat, with or without omeprazole or AlOH/MgOH, was well tolerated, with a good safety profile. The results confirm the lower bioavailability of riociguat in neutral versus acidic medium as expected from in vitro data. For co-medication of antacids like AlOH/MgOH, staggered intake between riociguat and antacid is practically possible and may be advisable. A general dose adaptation for patients with co-medication acting on gastric acidity, beyond the dose titration concept for riociguat, is not recommended.
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